AbbVie Bolsters Neuro Platform with $1B Syndesi Buy
Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at…
Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at…
Summary : Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will…
Synopsis: AbbVie’s blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn’s disease patients. The trial studied the AbbVie drug…